Eyad Almasri, MD
Critical Care (Intensivists) · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
- Since medical school
- 30 years
- Graduated 1996
Offices
5 locations · Central California Faculty Medical Group Inc · Fresno Community Hospital and Medical Center
Hospitals listed: Clovis Community Medical Center · Community Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Almasri’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A111780 · Current
Licensed to practise in California · since 2010 · expires 2027-05-31 · University of Damascus Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Critical Care Medicine
- American Board of Internal Medicine - Pulmonary Disease
- American Board of Internal Medicine - Sleep Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$57,223
Medicare paid this office $57,223 for 293 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 50 | $19,783 | $165 |
| Short return visit (20+ min) | 112 | $7,762 | $60 |
| New patient visit (45+ min) | 52 | $5,749 | $111 |
| Sleep study in sleep lab (6 years or older) | 11 | $5,573 | $507 |
| Return visit (30+ min) | 24 | $2,267 | $94 |
See all 13 services
| Critical care, first 30-74 minutes | 50 | $19,783 | $165 |
| Short return visit (20+ min) | 112 | $7,762 | $60 |
| New patient visit (45+ min) | 52 | $5,749 | $111 |
| Sleep study in sleep lab (6 years or older) | 11 | $5,573 | $507 |
| Return visit (30+ min) | 24 | $2,267 | $94 |
| Test to examine how well the lungs exchange gases | 28 | $1,340 | $48 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,024 | $93 |
| Test to determine lung volumes using sensors | 20 | $942 | $47 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 25 | $817 | $33 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 12 | $790 | $66 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 11 | $144 | $13 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 12 | $80 | $7 |
| Test to examine how well the lungs exchange gases | 11 | $62 | $6 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | – | 13 | – | 16 | 13 | – |
| Insertion of artery tube for blood sampling or infusion through skin | – | – | – | 13 | – | – |
| Emergent insertion of breathing tube into windpipe using an endoscope | 11 | – | – | – | – | – |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
293 Original Medicare patients in 2024. Average age 72 · Under 65 14% · 85 and older 9% · Women 45% · Also on Medicaid 38% · Health risk score 2.24. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Diabetes 51% · Coronary heart disease 49% · Heart failure 40% · Chronic kidney disease 37% · COPD 35% · Atrial fibrillation 29% · Depression 25% · Cancer 15% · Stroke 15% · Dementia 12%.
The office billed $211,547, Medicare allowed $76,716 and paid $57,223; for 580 services of 36 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 293 | 580 | 72 | 2.24 | $211,547 | $57,223 |
| 2023 | 307 | 525 | 71 | 2.11 | $228,890 | $64,419 |
| 2022 | 370 | 631 | 71 | 2.04 | $260,457 | $71,699 |
| 2021 | 391 | 704 | 71 | 2.18 | $267,029 | $79,762 |
| 2020 | 442 | 809 | 70 | 2.41 | $305,581 | $90,220 |
| 2019 | 507 | 1,043 | 71 | 2.51 | $380,719 | $101,589 |
| 2018 | 434 | 882 | 70 | 2.45 | $374,114 | $104,739 |
| 2017 | 506 | 863 | 69 | 2.43 | $440,499 | $121,848 |
| 2016 | 433 | 787 | 69 | 2.31 | $281,702 | $83,416 |
| 2015 | 474 | 938 | 70 | 2.45 | $432,543 | $127,039 |
| 2014 | 408 | 875 | 70 | 2.26 | $463,879 | $127,935 |
| 2013 | 501 | 1,140 | 71 | 2.39 | $480,262 | $139,375 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Critical care, first 30-74 minutes | 63 | $24,036 | $170 |
| Sleep study in sleep lab (6 years or older) | 16 | $8,316 | $520 |
| New patient visit (45+ min) | 49 | $6,211 | $127 |
| Short return visit (20+ min) | 84 | $6,092 | $73 |
| Return visit (30+ min) | 51 | $5,451 | $99 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 12 | $871 | $67 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 11 | $859 | $78 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 14 | $114 | $8 |
| Test to examine how well the lungs exchange gases | 14 | $98 | $7 |
2022: 14 services
| Critical care, first 30-74 minutes | 90 | $30,727 | $175 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 17 | $8,913 | $524 |
| Short return visit (20+ min) | 70 | $5,034 | $65 |
| New patient visit (45+ min) | 32 | $4,164 | $130 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $3,560 | $108 |
| Return visit (30+ min) | 33 | $3,505 | $100 |
| Sleep study including heart rate, breathing, and sleep time | 11 | $1,490 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,308 | $82 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 16 | $1,081 | $68 |
| Insertion of artery tube for blood sampling or infusion through skin | 13 | $462 | $36 |
| Test to determine lung volumes using sensors | 30 | $273 | $9 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 30 | $242 | $8 |
| Test to examine how well the lungs exchange gases | 33 | $223 | $7 |
| Test to measure expiratory airflow and volume | 15 | $106 | $6 |
2021: 11 services
| Critical care, first 30-74 minutes | 110 | $43,183 | $177 |
| Short return visit (20+ min) | 89 | $7,276 | $73 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $4,486 | $109 |
| New patient visit (45+ min) | 31 | $4,313 | $139 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 24 | $3,704 | $154 |
| Return visit (30+ min) | 16 | $1,715 | $107 |
| Test for exercise-induced lung stress | 15 | $260 | $17 |
| Test to determine lung volumes using sensors | 24 | $240 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $222 | $9 |
| Test to examine how well the lungs exchange gases | 30 | $222 | $7 |
| Test to measure expiratory airflow and volume | 20 | $136 | $7 |
2020: 14 services
| Critical care, first 30-74 minutes | 125 | $46,714 | $182 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 61 | $7,346 | $115 |
| Short return visit (20+ min) | 83 | $4,730 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,413 | $88 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 20 | $3,387 | $169 |
| New patient visit (45+ min) | 21 | $2,607 | $124 |
| Return visit (30+ min) | 28 | $2,395 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,574 | $61 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 12 | $931 | $72 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 38 | $412 | $11 |
| Test to determine lung volumes using sensors | 37 | $378 | $10 |
| Test for exercise-induced lung stress | 17 | $324 | $19 |
| Test to examine how well the lungs exchange gases | 42 | $318 | $8 |
| Test to measure expiratory airflow and volume | 15 | $105 | $7 |
2019: 16 services
| Critical care, first 30-74 minutes | 77 | $31,285 | $177 |
| Sleep study in sleep lab (6 years or older) | 27 | $13,015 | $482 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 94 | $10,823 | $106 |
| Short return visit (20+ min) | 109 | $7,320 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $6,881 | $84 |
| New patient visit (45+ min) | 45 | $5,892 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $3,640 | $59 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 15 | $2,580 | $172 |
| Long return visit (40+ min) | 11 | $1,311 | $119 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 11 | $1,252 | $114 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | $1,154 | $105 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 76 | $763 | $10 |
| Test to examine how well the lungs exchange gases | 79 | $552 | $7 |
| Test to determine lung volumes using gas dilution or washout | 40 | $353 | $9 |
| Test to determine lung volumes using sensors | 23 | $232 | $10 |
| Test to measure expiratory airflow and volume | 18 | $124 | $7 |
2018: 13 services
| Critical care, first 30-74 minutes | 106 | $45,737 | $177 |
| Sleep study in sleep lab (6 years or older) | 23 | $11,637 | $506 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 73 | $8,272 | $109 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 15 | $7,755 | $517 |
| Short return visit (20+ min) | 96 | $5,406 | $50 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $5,123 | $59 |
| New patient visit (45+ min) | 28 | $3,446 | $123 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 20 | $3,124 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $2,699 | $84 |
| Return visit (30+ min) | 14 | $1,326 | $83 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | $352 | $10 |
| Test to determine lung volumes using gas dilution or washout | 32 | $292 | $9 |
| Test to examine how well the lungs exchange gases | 36 | $246 | $7 |
2017: 12 services
| Critical care, first 30-74 minutes | 127 | $49,797 | $171 |
| Sleep study in sleep lab (6 years or older) | 39 | $19,856 | $509 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 25 | $13,368 | $535 |
| Short return visit (20+ min) | 156 | $9,488 | $53 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 67 | $7,098 | $106 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 32 | $4,729 | $148 |
| New patient visit (45+ min) | 34 | $4,239 | $125 |
| Long return visit (40+ min) | 15 | $1,429 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,263 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $995 | $83 |
| Return visit (30+ min) | 11 | $952 | $87 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $315 | $16 |
2016: 13 services
| Critical care, first 30-74 minutes | 92 | $35,760 | $179 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 74 | $8,306 | $109 |
| Short return visit (20+ min) | 117 | $6,857 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $4,803 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $3,741 | $58 |
| New patient visit (45+ min) | 31 | $3,717 | $120 |
| Long return visit (40+ min) | 22 | $2,581 | $117 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 12 | $2,050 | $171 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 13 | $1,468 | $113 |
| Test to determine lung volumes using gas dilution or washout | 28 | $283 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 21 | $225 | $11 |
| Test to examine how well the lungs exchange gases | 29 | $217 | $7 |
| Test to measure expiratory airflow and volume | 12 | $83 | $7 |
2015: 13 services
| Critical care, first 30-74 minutes | 172 | $72,087 | $177 |
| Sleep study in sleep lab (6 years or older) | 18 | $9,248 | $514 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 67 | $7,645 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $7,225 | $84 |
| Return visit (30+ min) | 79 | $7,057 | $81 |
| New patient visit (45+ min) | 26 | $3,329 | $128 |
| Short return visit (20+ min) | 39 | $2,476 | $59 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 13 | $2,232 | $172 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 16 | $2,057 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,827 | $59 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 22 | $236 | $11 |
| Test to determine lung volumes using gas dilution or washout | 19 | $182 | $10 |
| Test to examine how well the lungs exchange gases | 17 | $120 | $7 |
2014: 11 services
| Critical care, first 30-74 minutes | 174 | $72,301 | $178 |
| Sleep study in sleep lab (6 years or older) | 28 | $14,357 | $513 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $9,056 | $84 |
| Return visit (30+ min) | 85 | $7,934 | $79 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 11 | $6,012 | $547 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $5,315 | $111 |
| New patient visit (45+ min) | 16 | $1,905 | $119 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 18 | $1,538 | $85 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 19 | $192 | $10 |
| Test to determine lung volumes using gas dilution or washout | 13 | $121 | $9 |
| Test to examine how well the lungs exchange gases | 14 | $97 | $7 |
2013: 14 services
| Critical care, first 30-74 minutes | 173 | $71,102 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 73 | $15,503 | $82 |
| Return visit (30+ min) | 108 | $10,734 | $83 |
| Sleep study in sleep lab (6 years or older) | 16 | $8,731 | $546 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 73 | $8,556 | $108 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 12 | $6,859 | $572 |
| New patient visit (45+ min) | 37 | $4,858 | $131 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 24 | $2,226 | $93 |
| Diagnostic exam of lung airway using an endoscope | 12 | $1,413 | $118 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 46 | $493 | $10 |
| Test to determine lung volumes using gas dilution or washout | 28 | $293 | $10 |
| Test to examine how well the lungs exchange gases | 28 | $215 | $8 |
| Exam of lung airways using an endoscope | 12 | $132 | $11 |
| Test to measure expiratory airflow and volume | 19 | $124 | $7 |
Medicaid work
$16,492 in 2024
Medicaid paid $16,492 for 316 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 27 | $10,279 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 161 | $4,991 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 54 | $985 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 13 | $117 |
| Short return visit (20+ min) | 25 | $82 |
| Return visit (30+ min) | 36 | $38 |
| 2024 | 316 | 6 | 27 | $16,492 |
| 2023 | 538 | 9 | 25 | $31,906 |
| 2022 | 572 | 5 | 34 | $25,380 |
| 2021 | 477 | 6 | 26 | $39,851 |
| 2020 | 587 | 5 | 45 | $58,165 |
| 2019 | 204 | 3 | 23 | $20,917 |
| 2018 | 297 | 3 | 34 | $15,628 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 61 | $21,525 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 255 | $9,902 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 44 | $165 |
| EVALUATION OF WHEEZING | 33 | $117 |
| Diffusing capacity | 36 | $90 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 15 | $68 |
| Short return visit (20+ min) | 61 | $24 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 13 | $16 |
| Return visit (30+ min) | 20 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 56 | $16,658 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 360 | $8,691 |
| Short return visit (20+ min) | 116 | $24 |
| Diffusing capacity | 26 | $7 |
| EVALUATION OF WHEEZING | 14 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 93 | $27,795 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 274 | $12,056 |
| EVALUATION OF WHEEZING | 12 | $0 |
| Diffusing capacity | 13 | $0 |
| Short return visit (20+ min) | 67 | $0 |
| Return visit (30+ min) | 18 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 142 | $34,729 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 358 | $23,243 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 13 | $193 |
| Short return visit (20+ min) | 54 | $0 |
| Return visit (30+ min) | 20 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 59 | $12,781 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 124 | $7,156 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 21 | $979 |
2018
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 254 | $12,107 |
| Clinic visit/encounter, all-inclusive | 12 | $2,625 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 31 | $896 |
Drugs they prescribed that Part D paid
$82,999
Pharmacies billed $82,999 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 245) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
83 generic and 162 brand-name prescriptions · $82,999 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 66 | $43,596 | $661 |
| Breo Ellipta | 40 | $15,973 | $399 |
| Qvar Redihaler | 11 | $3,093 | $281 |
| Fluticasone-Salmeterol | 13 | $1,736 | $134 |
| Fluticasone Propionate | 12 | $369 | $31 |
See all 6 drugs
| Trelegy Ellipta | 66 | $43,596 | $661 |
| Breo Ellipta | 40 | $15,973 | $399 |
| Qvar Redihaler | 11 | $3,093 | $281 |
| Fluticasone-Salmeterol | 13 | $1,736 | $134 |
| Fluticasone Propionate | 12 | $369 | $31 |
| Albuterol Sulfate Hfa | 12 | $302 | $25 |
Year by year
| 2024 | 245 | 74 | 0% (0) | 66% | $82,999 |
| 2023 | 202 | 54 | None | 69% | $78,267 |
| 2022 | 186 | 47 | 0% (0) | 78% | $75,269 |
| 2021 | 269 | 58 | 0% (0) | 68% | $85,310 |
| 2020 | 179 | 54 | 0% (0) | 56% | $46,578 |
| 2019 | 136 | 50 | 0% (0) | 74% | $39,397 |
| 2018 | 151 | 41 | 0% (0) | 77% | $46,054 |
| 2017 | 203 | 44 | None | 72% | $51,987 |
| 2016 | 164 | 48 | 0% (0) | 70% | $32,903 |
| 2015 | 98 | 34 | 0% (0) | 84% | $17,042 |
| 2014 | 138 | 34 | 0% (0) | 87% | $30,116 |
| 2013 | 198 | 67 | None | 80% | $40,720 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Trelegy Ellipta | 50 | $40,086 | $802 |
| Breo Ellipta | 37 | $16,133 | $436 |
| Albuterol Sulfate Hfa | 23 | $996 | $43 |
2022: 4 drugs
| Trelegy Ellipta | 62 | $43,093 | $695 |
| Breo Ellipta | 17 | $6,642 | $391 |
| Arnuity Ellipta | 12 | $2,459 | $205 |
| Albuterol Sulfate Hfa | 11 | $506 | $46 |
2021: 7 drugs
| Trelegy Ellipta | 51 | $35,151 | $689 |
| Breo Ellipta | 18 | $8,549 | $475 |
| Albuterol Sulfate Hfa | 46 | $2,587 | $56 |
| Arnuity Ellipta | 11 | $2,113 | $192 |
| Ventolin Hfa | 15 | $1,294 | $86 |
| Montelukast | 18 | $491 | $27 |
| Pantoprazole | 16 | $132 | $8 |
2020: 5 drugs
| Trelegy Ellipta | 26 | $14,738 | $567 |
| Spiriva | 11 | $5,036 | $458 |
| Arnuity Ellipta | 11 | $1,988 | $181 |
| Albuterol Sulfate Hfa | 18 | $1,200 | $67 |
| Gabapentin | 14 | $393 | $28 |
2019: 2 drugs
| Spiriva | 15 | $7,468 | $498 |
| Breo Ellipta | 11 | $5,385 | $490 |
2018: 5 drugs
| Advair Diskus | 19 | $10,476 | $551 |
| Breo Ellipta | 15 | $7,636 | $509 |
| Proair Hfa | 19 | $1,975 | $104 |
| Ventolin Hfa | 16 | $873 | $55 |
| Montelukast | 14 | $470 | $34 |
2017: 5 drugs
| Breo Ellipta | 36 | $15,693 | $436 |
| Advair Diskus | 28 | $13,947 | $498 |
| Proair Hfa | 17 | $2,078 | $122 |
| Ventolin Hfa | 25 | $1,449 | $58 |
| Montelukast | 20 | $342 | $17 |
2016: 6 drugs
| Breo Ellipta | 32 | $9,648 | $302 |
| Advair Diskus | 18 | $6,290 | $349 |
| Symbicort | 13 | $5,360 | $412 |
| Spiriva | 14 | $4,969 | $355 |
| Ventolin Hfa | 14 | $784 | $56 |
| Montelukast | 16 | $208 | $13 |
2015: 3 drugs
| Advair Diskus | 14 | $4,301 | $307 |
| Ventolin Hfa | 20 | $1,160 | $58 |
| Proair Hfa | 12 | $1,027 | $86 |
2014: 6 drugs
| Advair Diskus | 27 | $8,000 | $296 |
| Spiriva | 16 | $4,692 | $293 |
| Qvar | 13 | $3,385 | $260 |
| Symbicort | 12 | $3,086 | $257 |
| Ventolin Hfa | 24 | $1,251 | $52 |
| Omeprazole | 11 | $58 | $5 |
2013: 6 drugs
| Advair Diskus | 51 | $16,709 | $328 |
| Spiriva | 28 | $9,494 | $339 |
| Qvar | 23 | $4,396 | $191 |
| Symbicort | 16 | $3,797 | $237 |
| Ventolin Hfa | 13 | $617 | $47 |
| Proair Hfa | 12 | $569 | $47 |
Money from drug and device companies
$122 in 2025
| 2025 | 1 | 1 | None | $122 |
| 2024 | 2 | 2 | None | $156 |
| 2023 | 1 | 1 | None | $11 |
| 2022 | 1 | 2 | None | $43 |
| 2021 | 1 | 1 | None | $125 |
| 2019 | 1 | 1 | None | $143 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | None | $122 | 1 payment
|
See the published payment
| Genzyme | Meals · 2025-07-17 | None | $122 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $156
| Pfizer | Elrexfio | $127 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $29 | 1 payment
|
2023: $11
| Merck Sharp & Dohme | Zerbaxa | $11 | 1 payment
|
2022: $43
| Merck Sharp & Dohme | Zerbaxa | $43 | 2 payments
|
2021: $125
| Genzyme | None | $125 | 1 payment
|
2019: $143
| Insmed | None | $143 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biotest AG · A Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Phase III Trial To Assess the Efficacy and Safety of Trimodulin (Bt588) in Hospitalized Subjects With Severe Community-Acquired Pneumonia (Scap) · 2025 | Their institution | $126,869 |
| United Therapeutics Corporation · A Phase 4, Prospective, Multicenter, Single-Arm Study of A Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy To Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: Artisan (Afterload Reduction To Improve Right Ventricular Structure and Function) · 2024 | Their institution | $33,848 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial Tostudy the Safety, Tolerability, and Efficacy of Imipenem,Cilastatin,Relebactam Mk-7655aversus Piperacillin,Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia Orventilator-Associated Bacterial Pneumonia · 2020 | Their institution | $27,143 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 632521, Riociguat Users Registry the Roar Registry · 2024 | Their institution | $20,281 |
| Janssen Research & Development, LLC · Phase 2 Randomized Double Blind Placebo Controlled Study To Evaluate the Efficacy and Safety of Sirukumab in Confirmed Covid19 Severe Disease · 2021 | Their institution | $17,038 |
| United Therapeutics Corporation · A Phase 4, Prospective, Multicenter, Single-Arm Study of A Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy To Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: Artisan (Afterload Reduction To Improve Right Ventricular Structure and Function) · 2025 | Their institution | $14,731 |
| Merck Sharp & Dohme Corporation · A Prospective, Randomized, Double-Blind, Multicenter, Phase 3study To Assess the Safety and Efficacy of Intravenousceftolozane,Tazobactam Compared With Meropenem in Adultpatients With Ventilated Nosocomial Pneumonia · 2019 | Their institution | $11,890 |
| Merck Sharp & Dohme LLC · A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study To Assess the Safety and Efficacy of Intravenous Ceftolozane,Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia · 2023 | Their institution | $182 |
Professional record
- NPI
- 1992840490
- Licence
- CA A111780California A111780: Current · expires 2027-05-31
- Group
- Central California Faculty Medical Group Inc · Fresno Community Hospital and Medical Center
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RS0012X (207RS0012X)
- Mailing address
- 2625 E Divisadero St, Fresno, CA, 93721
- NPI first listed
- 2007-02-21
- NPI last updated
- 2024-09-16
- NPI record certified
- 2024-09-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2335 E Kashian Ln Ste 280, Fresno, CA, 93701